No headlines found.
Daxor Corporation Announces $9 Million Registered Direct Offering
Globe Newswire (Fri, 23-Jan 8:00 AM ET)
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Globe Newswire (Tue, 25-Nov 8:00 AM ET)
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Daxor - Closed End trades on the NASDAQ stock market under the symbol DXR.
As of February 3, 2026, DXR stock price climbed to $12.53 with 4,225 million shares trading.
DXR has a market cap of $73.04 million. This is considered a Micro Cap stock.
In the last 3 years, DXR traded as high as $14.76 and as low as $6.55.
The top ETF exchange traded funds that DXR belongs to (by Net Assets): VTI.
DXR has outperformed the market in the last year with a return of +61.1%, while the SPY ETF gained +16.6%. However, in the most recent history, DXR shares have underperformed the stock market with its stock returning -4.2% in the last 3 month period and -6.9% for the last 2 week period, while SPY has returned +1.2% and +1.8%, respectively.
DXR support price is $11.48 and resistance is $12.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DXR shares will trade within this expected range on the day.
